AI Article Synopsis
Article Abstract
Introduction: In Brazil, patients with ankylosing spondylitis (AS) have access to free-of-charge comprehensive therapeutic care through the Brazilian National Health System. We collected prospective data on patients with AS receiving anti-tumor necrosis factor (anti-TNF) therapy through the Brazilian National Health System in Belo Horizonte City in order to evaluate the effectiveness, quality-of-life outcomes and safety of this therapy.
Methods: This was a prospective study that included 87 patients receiving their first course of anti-TNF agents (adalimumab, etanercept or infliximab). The effectiveness of treatment was assessed at 6 and 12 months of follow-up using measures of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)], function [Health Assessment Questionnaire (HAQ)] and quality of life (EuroQol-5D). Good clinical response was defined as an improvement of at least 50% or 2 units in the BASDAI. Episodes of adverse events were recorded. Logistic regression was performed, and odds ratios (OR) with 95% confidence interval (95% CI) were calculated to estimate predictors of good clinical response at 6 months.
Results: At 6 months of follow-up, 64.9% of patients had a good clinical response, as evidenced by a drop in the median BASDAI score from 5.21 to 2.50 (p < 0.0001) and a reduction in the HAQ score from 1.13 to 0.38 (p < 0.0001). Patients also showed an improvement in health-related quality of life which was sustained after 12 months of follow-up. Female patients achieved a significantly lower clinical response than male patients (OR 0.29, 95% CI 0.11-0.78), but we observed no significant associations between the other variables. At the end of the study, 93 non-serious adverse events had been reported.
Conclusion: Treatment with the anti-TNF drugs adalimumab, etanercept and infliximab is effective and well tolerated in patients with AS. The improvement in disease activity, functional parameters and quality of life was sustained for 12 months.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999576 | PMC |
| http://dx.doi.org/10.1007/s40744-016-0026-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anatomy-centred deep learning improves generalisability and progression prediction in radiographic sacroiliitis detection.
RMD Open
December 2024
Department of Gastroenterology, Infectious Diseases and Rheumatology (incl. Nutrition Medicine), Charite - Universitatsmedizin Berlin, Berlin, Germany.
Purpose: To examine whether incorporating anatomy-centred deep learning can improve generalisability and enable prediction of disease progression.
Methods: This retrospective multicentre study included conventional pelvic radiographs of four different patient cohorts focusing on axial spondyloarthritis collected at university and community hospitals. The first cohort, which consisted of 1483 radiographs, was split into training (n=1261) and validation (n=222) sets.
Different disease activity trajectories in early axial spondyloarthritis lead to significantly different long-term outcomes: a trajectory-based analysis of the DESIR cohort over 10 years.
RMD Open
December 2024
Rheumatology, Hopital Cochin, Université Paris Descartes Faculté de Médecine, Paris, France.
Introduction: The study aimed to identify and describe disease activity trajectories over 10 years in patients with recent-onset axial spondyloarthritis (axSpA) and determine their impact on long-term outcomes.
Methods: This prospective, multicentre study (Devenir des Spondylarthropathies Indifférenciées Récentes cohort, ClinicalTrials.gov NCT) followed patients with early axSpA for 10 years.
Molecular Insights into the Therapeutic Mechanisms of BuShen-QiangDu-ZhiLv Decoction for Ankylosing Spondylitis.
J Ethnopharmacol
December 2024
Guangzhou University of Chinese Medicine, 510006 Guangzhou, China; State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine) 510120 Guangzhou, China; Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research Guangzhou University of Chinese Medicine, 510120 Guangzhou, China. Electronic address:
Ethnopharmacological Relevance: Ankylosing spondylitis (AS) is a chronic rheumatic immune disease characterized by high disability rates, significantly affecting patients' quality of life. BuShen-QiangDu-ZhiLv Decoction (BQZD), developed by the renowned traditional Chinese medicine practitioner Jiao Shude, has been traditionally used for AS treatment. However, the bioactive components and the precise mechanisms underlying BQZD's therapeutic effects remain largely unexplored.
View Article and Find Full Text PDFIdentifying prioritization of therapeutic targets for ankylosing spondylitis: a multi-omics Mendelian randomization study.
J Transl Med
December 2024
The First Affiliated Hospital of Chongqing Medical University, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Youyi Road 1, Chongqing, 400016, People's Republic of China.
Background: To investigate the associations of methylation, expression, and protein quantitative trait loci (mQTL, eQTL, and pQTL) with ankylosing spondylitis (AS) and find out genetically supported drug targets for AS.
Methods: The summary-data-based Mendelian randomization (SMR) and Bayesian co-localization analysis were used to assess the potential causality between AS and relevant genes. The GWAS data obtained from the International Genetics of Ankylosing Spondylitis Consortium (IGAS) were set as the discovery stage, and the FinnGen and UK Biobank databases were used to replicate the analysis as an external validation.
Evaluating methods for integrating single-cell data and genetics to understand inflammatory disease complexity.
Front Immunol
December 2024
Biofrontiers Institute, University of Colorado Boulder, Boulder, CO, United States.
Background: Understanding genetic underpinnings of immune-mediated inflammatory diseases is crucial to improve treatments. Single-cell RNA sequencing (scRNA-seq) identifies cell states expanded in disease, but often overlooks genetic causality due to cost and small genotyping cohorts. Conversely, large genome-wide association studies (GWAS) are commonly accessible.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!